Microvascular, anti-fibrotic & immunomodulatory tissue support
Stem cell therapy for scleroderma in Istanbul, Turkey
Our Istanbul medical team led by Uzm. Dr. Cihan Bolat reviews your scleroderma subtype, vascular symptoms, and organ evaluations to design an individualized Wharton's jelly MSC and exosome protocol.
Condition-specific editorial anatomy. Explanatory labels remain in accessible text.
Understanding the condition
Understanding the condition and our regenerative approach
Scleroderma (encompassing systemic sclerosis and localized morphea) is driven by an intricate triad of microvascular endothelial injury, autoimmune inflammation, and relentless fibroblast overactivation. When small blood vessels in the fingers, skin, and internal tissues suffer immune-mediated damage, local hypoxia and inflammatory signals stimulate resident fibroblasts to pour out dense, rigid collagen — leading to progressive skin tightening, painful Raynaud's vasospasm, digital ulcers, hand stiffness, and exhausting systemic fatigue that impacts every daily task.
Wharton's jelly-derived mesenchymal stem cells (WJ-MSCs) and WJ-MSC-derived exosomes are investigated in scleroderma because they simultaneously target all three pillars of this disease process: vascular injury, immune dysregulation, and tissue fibrosis. Once infused, WJ-MSCs release potent immunomodulatory cytokines (IL-10, PGE2) that calm autoreactive B-cells and T-cells and shift pro-inflammatory M1 macrophages into reparative M2 phenotypes, while secreting pro-angiogenic growth factors (VEGF, HGF, bFGF) that nourish damaged microvascular endothelium and promote new capillary sprouting. In parallel, nanoscale WJ-MSC exosomes transfer anti-fibrotic microRNAs (such as miR-29 and let-7 family members) and hepatocyte growth factor directly to overactive myofibroblasts — helping downregulate TGF-beta, CTGF, and Smad2/3 signaling so rigid collagen deposition slows and dermal and connective tissues can regain greater softness and elasticity.
At our Istanbul clinic, Uzm. Dr. Cihan Bolat and our medical team carefully evaluate your rheumatology history, autoantibody profile, echocardiogram, and pulmonary function tests to design a safe, individualized WJ-MSC and exosome protocol alongside your ongoing rheumatologist's care. Our goal is to support warmer microvascular circulation, softer and more flexible skin, improved hand mobility, and stronger daily vitality.
Reviewed by: Uzm. Dr. Cihan Bolat · Reviewed · Re-review due
What happens inside the body
Key biological processes and therapeutic targets
Scleroderma links autoimmune vascular injury directly to TGF-beta-driven fibroblast overactivation. Regenerative medicine is investigated for its dual capacity to calm autoimmune signaling while delivering angiogenic and anti-fibrotic factors to remodel stiffened tissue.
What our protocol aims to support
- Supporting microvascular circulation & digital comfort: Delivering pro-angiogenic and endothelial-supportive paracrine signals aimed at improving capillary microenvironment health, digital warmth, and ulcer recovery.
- Modulating TGF-beta & fibrotic tissue signaling: Using WJ-MSCs and exosomal microRNAs to help temper overactive myofibroblast signaling and support softer, more pliable dermal and connective tissue homeostasis.
- Calming systemic autoimmune inflammation: Promoting regulatory T-cell balance and M2 macrophage polarization to help reduce systemic stiffness, joint discomfort, and chronic inflammatory fatigue.
- Coordinated alongside your home rheumatologist: Your Istanbul regenerative program is designed to work in harmony with the vasoactive, immunomodulatory, or antifibrotic medications prescribed by your rheumatologist.
- 01
Microvascular endothelial injury & Raynaud's ischemia
The earliest biological event in scleroderma is apoptosis and dysfunction of microvascular endothelial cells, which depletes vasodilatory nitric oxide and prostacyclin while increasing vasoconstrictive endothelin-1. As capillaries narrow and disappear, patients experience severe Raynaud's vasospasm, cold digits, painful digital ulcers, and chronic tissue hypoxia. Wharton's jelly MSCs and exosomes release VEGF, HGF, and anti-apoptotic microRNAs that shield endothelial cells from oxidative death and stimulate microvascular repair. Restoring capillary health helps improve digital perfusion, warm cold extremities, and support the healing of ischemic skin lesions.
- 02
Autoimmune B-cell & T-cell inflammatory activation
Perivascular infiltrates of activated T-cells (Th2/Th17), B-cells, and plasmacytoid dendritic cells produce scleroderma-specific autoantibodies and secrete IL-4, IL-6, IL-13, and type I interferons that directly stimulate collagen synthesis. This persistent autoimmune fire keeps connective tissues in a state of chronic injury and fuels systemic fatigue and joint aching. WJ-MSCs counter this immune dysregulation by expanding FoxP3+ regulatory T-cells (Tregs), dampening B-cell hyperreactivity, and converting pro-inflammatory M1 macrophages into reparative M2 macrophages. Calming this perivascular immune storm reduces the upstream biochemical signals that drive fibrosis.
- 03
Excessive TGF-beta & myofibroblast activation
Transforming growth factor-beta (TGF-beta), along with CTGF and PDGF, acts as the master switch of fibrosis in scleroderma, converting resident dermal and stromal fibroblasts into persistently contracted myofibroblasts. Even after initial inflammation subsides, these myofibroblasts continue overproducing type I and type III collagen and fibronectin while resisting normal programmed cell death. WJ-MSC-derived exosomes deliver targeted microRNAs (including miR-29a and miR-145 modulators) and HGF that inhibit TGF-beta/Smad2/3 phosphorylation inside myofibroblasts. Tempering this master fibrotic switch helps halt runaway scar deposition and encourages a return toward normal fibroblast behavior.
- 04
Dermal & visceral extracellular matrix stiffening
As cross-linked collagen bundles accumulate in the dermis and subcutaneous layers, the skin loses its natural pliability, tethering down over fingers, wrists, face, and joints and restricting grip strength and range of motion. In systemic sclerosis, similar microvascular and fibrotic remodeling can also strain the pulmonary interstitium and gastrointestinal tract. Paracrine factors from WJ-MSCs and exosomes help rebalance matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs), supporting gradual remodeling of dense collagen fibers. This biological support aims to improve skin softness (mRSS), finger flexion, and overall tissue suppleness.
Why regenerative medicine is investigated
Scientific rationale for Wharton's jelly MSCs and exosomes
Addressing the Vascular-Immune-Fibrotic Triad
Scleroderma progresses because endothelial cell injury in small capillaries triggers perivascular immune infiltration, which in turn floods surrounding tissue with TGF-beta and PDGF. Under this constant biochemical pressure, normal fibroblasts transform into alpha-SMA-positive myofibroblasts that lock the dermis and connective tissues in a rigid collagen matrix. Regenerative medicine is investigated because single-target drugs rarely address microvascular loss, immune activation, and fibrosis at the same time. By intervening across all three pathways, biological therapy aims to interrupt the self-sustaining cycle of ischemia and scarring.
Angiogenic & Anti-Fibrotic Action of WJ-MSCs & Exosomes
Wharton's jelly-derived MSCs (WJ-MSCs) secrete vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), and angiopoietins that protect injured endothelial cells, improve nitric-oxide-mediated vasodilation, and encourage capillary regeneration in ischemic digits and skin. Simultaneously, WJ-MSCs calm autoreactive T-cell and B-cell signaling and polarize macrophages toward the pro-resolving M2 phenotype. Complementing the cells, nanoscale WJ-MSC exosomes penetrate dense fibrotic matrices to deliver anti-fibrotic microRNAs that suppress TGF-beta/Smad signaling and support healthy matrix metalloproteinase (MMP) balance, helping soften thickened dermal tissue.
Cardiopulmonary-Screened Individualized Protocol
Because systemic sclerosis can involve the lungs, heart, and kidneys alongside the skin, thorough specialist screening is the cornerstone of safe protocol design in Istanbul. Uzm. Dr. Cihan Bolat and our medical team review your subtype (limited vs. diffuse cutaneous systemic sclerosis or morphea), echocardiogram, pulmonary function tests (FVC, DLCO), renal labs, and current rheumatology medications before confirming your treatment plan. We tailor the exact GMP-certified WJ-MSC dosage, exosome concentration, infusion rate, and delivery routes to your organ profile, followed by structured 1, 3, and 6-month clinical tracking.
Our treatment approach & administration routes
How our proposed Wharton's jelly MSC and exosome protocols work
- 01
Intravenous Wharton's Jelly MSC (WJ-MSC) Infusion
Intravenous administration delivers GMP-certified Wharton's jelly MSCs into the systemic circulation, where they release a coordinated repertoire of immunomodulatory cytokines (IL-10, PGE2), angiogenic growth factors (VEGF, HGF), and anti-fibrotic signals. Because intravenously infused MSCs interact intimately with the pulmonary and systemic microvascular beds, they are uniquely positioned to calm perivascular autoimmune inflammation and shift macrophages from pro-fibrotic M1/M2a states toward matrix-remodeling M2c phenotypes. This systemic action supports both dermal pliability and microvascular endothelial recovery in fingers and extremities. Infusions are administered under close clinical monitoring tailored to your cardiopulmonary baseline.
Role in your protocolOur medical team determines the exact Wharton's jelly MSC and exosome combination, dosage, and administration route after evaluating your medical history and reports.
- 02
Intravenous WJ-MSC-Derived Exosome Administration
WJ-MSC-derived exosomes are nanoscale extracellular vesicles (30–150 nm) capable of diffusing through dense, collagen-rich fibrotic tissues and narrowed microvessels that whole cells cannot easily penetrate. They carry a concentrated cargo of anti-fibrotic microRNAs, hepatocyte growth factor (HGF), and angiogenic proteins directly to dermal myofibroblasts and ischemic capillary endothelium. Inside these target cells, exosomes help downregulate TGF-beta/Smad signaling, reduce excessive collagen cross-linking, and stimulate endothelial repair. We note transparently that while cellular and exosomal pathways complement each other biologically, whether combined MSC and exosome therapy outperforms single-modality treatment remains under clinical investigation.
Role in your protocolOur medical team determines the exact Wharton's jelly MSC and exosome combination, dosage, and administration route after evaluating your medical history and reports.
- 03
Intramuscular Administration (When Included in Your Protocol)
In selected scleroderma protocols, intramuscular delivery is included to create a sustained local biological depot within healthy muscle tissue. While intravenous MSCs undergo rapid initial interaction with the pulmonary vasculature, intramuscularly placed cells remain viable locally for an extended period and release a continuous stream of anti-fibrotic microRNAs, angiogenic factors, and immunomodulatory cytokines into the systemic circulation. This gradual paracrine release helps maintain steady anti-TGF-beta and vascular-supportive signaling over the weeks following your Istanbul visit. We distinguish this biological depot rationale from established clinical trial proof of pharmacokinetic superiority.
Role in your protocolOur medical team determines the exact Wharton's jelly MSC and exosome combination, dosage, and administration route after evaluating your medical history and reports.
What we aim to achieve
Therapeutic objectives and functional outcomes we track
Before treatment in Istanbul, our physicians establish your clinical baseline and define realistic biological and functional objectives to track during follow-up.
- 01
Skin Softness, Pliability & mRSS Trajectory
By downregulating TGF-beta myofibroblast activity and supporting balanced collagen remodeling, our protocol aims to help soften tightened skin and improve Modified Rodnan Skin Score (mRSS) trends.
- 02
Microvascular Perfusion, Raynaud's & Digital Comfort
Delivering pro-angiogenic VEGF and HGF signals to damaged capillaries helps support warmer hands and feet, fewer and milder Raynaud's attacks, and healthier recovery of digital skin ulcers.
- 03
Hand Grip, Finger Flexion & Joint Mobility
Reducing dermal tethering and soothing periarticular tendon and synovial inflammation helps restore finger dexterity, grip strength, and comfort during everyday tasks like writing, dressing, and eating.
- 04
Systemic Energy & Cardiopulmonary Stability
Calming chronic autoimmune cytokine activity supports better daily stamina and sleep while working alongside your home rheumatologist to preserve stable pulmonary and systemic organ function.
How treatment is personalized
How our medical team evaluates your records and designs your protocol
Our Istanbul medical team led by Uzm. Dr. Cihan Bolat reviews your scleroderma subtype, vascular symptoms, and organ evaluations to design an individualized Wharton's jelly MSC and exosome protocol.
Medical history & reports we request
- Confirmed diagnosis of systemic sclerosis (limited or diffuse) or localized morphea
- Recent rheumatology notes, autoantibody panel, and inflammatory markers (CRP, ESR)
- Recent echocardiogram, pulmonary function tests (FVC, DLCO), and chest HRCT if applicable
- Blood pressure log, renal function panel (creatinine, eGFR), and digital ulcer history
- Current rheumatology and vasoactive medication list
Clinical suitability & protocol checks
- Our medical team reviews your cardiac, pulmonary, and renal reports carefully before confirming suitability and infusion volume parameters for your Istanbul visit.
- Patients continue their prescribed vasodilators, immunosuppressants, or antifibrotic medicines under their home rheumatologist's supervision.
- Acute cardiopulmonary instability, severe pulmonary arterial hypertension, or scleroderma renal crisis requires local specialist care rather than elective travel.
What the patient journey looks like
From your first inquiry to individualized treatment in Istanbul
- 01
Contact us & share your medical reports
Reach out regarding your condition and share your medical history, diagnosis, imaging, and relevant lab reports via our secure form or WhatsApp.
- 02
Medical team evaluation & protocol design
Our medical team evaluates your records and, where clinically appropriate, develops an individualized Wharton's jelly MSC and exosome protocol.
- 03
Transparent explanation of protocol & costs
We explain the proposed treatment, specific biologics, administration routes, intended therapeutic objectives, stay timeline, and itemized costs.
- 04
Arrange treatment in Istanbul & follow-up
Review your individualized proposal, schedule your visit to Istanbul with private airport and clinic transfers, and continue with structured 1, 3, and 6-month follow-up.
2026 cost & protocol planning
Transparent Istanbul pricing tailored to your protocol
After our medical team evaluates your records, we provide a written proposal explaining the recommended Wharton's jelly MSC and exosome preparations, administration routes, intended objectives, stay timeline, and itemized costs.
For 2026 planning context, targeted exosome and local orthopedic protocols typically range from $3,500–$6,500, while comprehensive Wharton's jelly MSC and exosome programs range from $7,000–$18,000. Your exact cost is confirmed after your medical evaluation.
- Our medical team reviews your cardiac, pulmonary, and renal reports carefully before confirming suitability and infusion volume parameters for your Istanbul visit.
- Patients continue their prescribed vasodilators, immunosuppressants, or antifibrotic medicines under their home rheumatologist's supervision.
- Acute cardiopulmonary instability, severe pulmonary arterial hypertension, or scleroderma renal crisis requires local specialist care rather than elective travel.
What your written treatment proposal explains
- 01
Which Wharton's jelly MSC, exosome, or combined protocol is proposed for your condition?
- 02
Which administration routes are recommended and how do they work biologically?
- 03
What are the intended therapeutic objectives and expected stay length in Istanbul?
- 04
What is the itemized cost and how does 1, 3, and 6-month follow-up work after treatment?
Evidence & important considerations
Published clinical research and important considerations
Below is a summary of published human studies, investigated mechanisms, and important limitations relevant to regenerative medicine for this condition.
01 EULAR recommendations for systemic sclerosis management
Open study- Product
- Organ-directed immunomodulatory, vasoactive, and antifibrotic medical care
- Route
- Standard rheumatology care pathways
- Study design
- Evidence-based international rheumatology consensus guideline
- Finding
- Establishes the importance of ongoing rheumatologic and cardiopulmonary monitoring as the foundation alongside which any supportive therapy is planned.
- Limitation
- Supportive mesenchymal stromal cell and exosome protocols complement rather than replace guideline-directed rheumatology medications.
02 Mesenchymal stromal cells in systemic sclerosis clinical research
Open study- Product
- Umbilical cord and Wharton's jelly mesenchymal stromal cells
- Route
- Intravenous systemic infusion
- Study design
- Early-phase clinical and translational studies in systemic sclerosis
- Finding
- Clinical studies explore immune-modulatory, pro-angiogenic, and anti-fibrotic signals for skin elasticity (mRSS), Raynaud's severity, and digital ulcer recovery.
- Limitation
- Individual responses vary by disease duration and organ baseline, and careful cardiopulmonary screening is required prior to elective treatment.
Scientific references
Clinical studies and scientific references
FAQ
Frequently asked questions about this treatment
Request Free Medical Evaluation
Begin a personalized treatment conversation with our medical team.
Share your case in confidence. Our international coordinators review every enquiry and respond within 24 hours, in your language.